Literature DB >> 20601092

Rho-kinase inhibition: a novel therapeutic target for the treatment of cardiovascular diseases.

Ming Dong1, Bryan P Yan, James K Liao, Yat-Yin Lam, Gabriel W K Yip, Cheuk-Man Yu.   

Abstract

The Rho/rho-kinase (ROCK) pathway has an important role in the pathogenesis of several cardiovascular diseases. The activation of ROCK is involved in the regulation of vascular tone, endothelial dysfunction, inflammation and remodeling. The inhibition of ROCK has a beneficial effect in a variety of cardiovascular disorders. Evidence from animal models and from clinical use of ROCK inhibitors, such as Y-27632, fasudil and statins (i.e. pleiotropic effects), supports the hypothesis that ROCK is a potential therapeutic target. This review provides a current understanding of the role of ROCK pathway in the regulation of vascular function and the use of ROCK inhibitors in the treatment of cardiovascular disorders.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20601092      PMCID： PMC3807099          DOI： 10.1016/j.drudis.2010.06.011

Source DB:  PubMed          Journal:  Drug Discov Today        ISSN： 1359-6446            Impact factor:   7.851


  118 in total

1.  Multiple signalling pathways lead to the activation of the nuclear factor kappaB by the Rho family of GTPases.

Authors:  S Montaner; R Perona; L Saniger; J C Lacal
Journal:  J Biol Chem       Date:  1998-05-22       Impact factor: 5.157

2.  Localization of the gene coding for ROCK II/Rho kinase on human chromosome 2p24.

Authors:  N Takahashi; H Tuiki; H Saya; K Kaibuchi
Journal:  Genomics       Date:  1999-01-15       Impact factor: 5.736

3.  Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors.

Authors:  U Laufs; V La Fata; J Plutzky; J K Liao
Journal:  Circulation       Date:  1998-03-31       Impact factor: 29.690

4.  An essential part for Rho-associated kinase in the transcellular invasion of tumor cells.

Authors:  K Itoh; K Yoshioka; H Akedo; M Uehata; T Ishizaki; S Narumiya
Journal:  Nat Med       Date:  1999-02       Impact factor: 53.440

5.  Enhanced myosin light chain phosphorylations as a central mechanism for coronary artery spasm in a swine model with interleukin-1beta.

Authors:  N Katsumata; H Shimokawa; M Seto; T Kozai; T Yamawaki; K Kuwata; K Egashira; I Ikegaki; T Asano; Y Sasaki; A Takeshita
Journal:  Circulation       Date:  1997-12-16       Impact factor: 29.690

6.  Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension.

Authors:  M Uehata; T Ishizaki; H Satoh; T Ono; T Kawahara; T Morishita; H Tamakawa; K Yamagami; J Inui; M Maekawa; S Narumiya
Journal:  Nature       Date:  1997-10-30       Impact factor: 49.962

Review 7.  Coronary spasm: clinical features and pathogenesis.

Authors:  H Yasue; K Kugiyama
Journal:  Intern Med       Date:  1997-11       Impact factor: 1.271

Review 8.  Potential role of the adventitia in arteritis and atherosclerosis.

Authors:  J N Wilcox; N A Scott
Journal:  Int J Cardiol       Date:  1996-08       Impact factor: 4.164

9.  p115 RhoGEF, a GTPase activating protein for Galpha12 and Galpha13.

Authors:  T Kozasa; X Jiang; M J Hart; P M Sternweis; W D Singer; A G Gilman; G Bollag; P C Sternweis
Journal:  Science       Date:  1998-06-26       Impact factor: 47.728

10.  3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors increase fibrinolytic activity in rat aortic endothelial cells. Role of geranylgeranylation and Rho proteins.

Authors:  M Essig; G Nguyen; D Prié; B Escoubet; J D Sraer; G Friedlander
Journal:  Circ Res       Date:  1998-10-05       Impact factor: 17.367
View more
  49 in total

1.  Elaborate ligand-based modeling reveal new submicromolar Rho kinase inhibitors.

Authors:  Rand Shahin; Saja Alqtaishat; Mutasem O Taha
Journal:  J Comput Aided Mol Des       Date:  2011-12-14       Impact factor: 3.686

2.  Fragment-based and structure-guided discovery and optimization of Rho kinase inhibitors.

Authors:  Rongshi Li; Mathew P Martin; Yan Liu; Binglin Wang; Ronil A Patel; Jin-Yi Zhu; Nan Sun; Roberta Pireddu; Nicholas J Lawrence; Jiannong Li; Eric B Haura; Shen-Shu Sung; Wayne C Guida; Ernst Schonbrunn; Said M Sebti
Journal:  J Med Chem       Date:  2012-02-15       Impact factor: 7.446

Review 3.  Role of rho kinase in the functional and dysfunctional tonic smooth muscles.

Authors:  Márcio A F de Godoy; Satish Rattan
Journal:  Trends Pharmacol Sci       Date:  2011-04-15       Impact factor: 14.819

Review 4.  Rho kinases in cardiovascular physiology and pathophysiology: the effect of fasudil.

Authors:  Jianjian Shi; Lei Wei
Journal:  J Cardiovasc Pharmacol       Date:  2013-10       Impact factor: 3.105

5.  Partial contribution of Rho-kinase inhibition to the bioactivity of Ganoderma lingzhi and its isolated compounds: insights on discovery of natural Rho-kinase inhibitors.

Authors:  Yhiya Amen; Qinchang Zhu; Hai-Bang Tran; Mohamed S Afifi; Ahmed F Halim; Ahmed Ashour; Kuniyoshi Shimizu
Journal:  J Nat Med       Date:  2017-01-10       Impact factor: 2.343

6.  ROCK inhibitor and feeder cells induce the conditional reprogramming of epithelial cells.

Authors:  Xuefeng Liu; Virginie Ory; Sandra Chapman; Hang Yuan; Chris Albanese; Bhaskar Kallakury; Olga A Timofeeva; Caitlin Nealon; Aleksandra Dakic; Vera Simic; Bassem R Haddad; Johng S Rhim; Anatoly Dritschilo; Anna Riegel; Alison McBride; Richard Schlegel
Journal:  Am J Pathol       Date:  2011-12-18       Impact factor: 4.307

Review 7.  Rho kinase as a therapeutic target in cardiovascular disease.

Authors:  Michelle Surma; Lei Wei; Jianjian Shi
Journal:  Future Cardiol       Date:  2011-09

8.  Targeting the Mevalonate Pathway Suppresses VHL-Deficient CC-RCC through an HIF-Dependent Mechanism.

Authors:  Jordan M Thompson; Alejandro Alvarez; Monika K Singha; Matthew W Pavesic; Quy H Nguyen; Luke J Nelson; David A Fruman; Olga V Razorenova
Journal:  Mol Cancer Ther       Date:  2018-05-02       Impact factor: 6.261

9.  Leiomyoma cells in 3-dimensional cultures demonstrate an attenuated response to fasudil, a rho-kinase inhibitor, when compared to 2-dimensional cultures.

Authors:  Minnie Malik; Joy Britten; James Segars; William H Catherino
Journal:  Reprod Sci       Date:  2014-08-01       Impact factor: 3.060

10.  Central Angiotensin-II Increases Blood Pressure and Sympathetic Outflow via Rho Kinase Activation in Conscious Rabbits.

Authors:  Peter R Pellegrino; Alicia M Schiller; Karla K V Haack; Irving H Zucker
Journal:  Hypertension       Date:  2016-09-26       Impact factor: 10.190
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.